Figure 5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• Tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in cancer patients.
• Patients with head and neck squamous cell carcinoma achieved complete response after 15 months of therapy.
• Assessment involved monitoring tumor fraction using ctDNA across various cancer types including NSCLC and endometrial carcinoma.
• Study suggests monitoring tumor fraction may enable more personalized treatment approaches in oncology.